帕博利珠单抗联合化疗治疗宫颈癌:KEYNOTE-826随机临床试验探索性分析
该研究为KEYNOTE-826三期双盲随机试验的探索性分析,纳入617例既往未治疗的持续性、复发性或转移性宫颈癌患者,中位随访59.1个月。结果显示,帕博利珠单抗联合化疗(±贝伐珠单抗)在PD-L1 CPS≥1和ITT人群中均持续改善总生存和无进展生存,5年获益持久,未发现新安全信号。
要点
- 5年随访证实帕博利珠单抗联合化疗一线治疗持续改善OS和PFS。
- PD-L1 CPS≥1人群OS HR 0.62,ITT人群HR 0.64。
- 安全性可控,未观察到新安全信号。
核心结论
- 5年数据证实帕博利珠单抗联合化疗(±贝伐珠单抗)一线治疗持续性、复发性或转移性宫颈癌的获益持久。
研究设计与样本
- KEYNOTE-826三期双盲随机临床试验的探索性分析,覆盖19个国家151个中心。
- 共随机617例既往未治疗的持续性、复发性或转移性宫颈癌女性患者。
- 帕博利珠单抗200 mg每3周最多35周期对比安慰剂,联合铂类化疗(±贝伐珠单抗)。
- 中位随访59.1个月(范围52.1-66.5),约在最终分析后20个月。
主要发现
- PD-L1 CPS≥1人群:帕博利珠单抗组中位OS 28.6个月(IQR 12.3至未达到)vs 16.5个月(9.0-40.5),HR 0.62(95%CI 0.50-0.76)。
- ITT人群:中位OS 26.4个月(12.0至未达到)vs 16.8个月(9.1-40.1),HR 0.64(95%CI 0.53-0.78)。
- PD-L1 CPS≥1人群:中位PFS 10.5个月(6.2至未达到)vs 8.2个月(4.2-17.1),HR 0.58(95%CI 0.48-0.71)。
- ITT人群:中位PFS 10.4个月(6.2至未达到)vs 8.2个月(4.3-15.5),HR 0.61(95%CI 0.51-0.74)。
- 未观察到新安全信号,自最终分析以来未发生额外的治疗相关不良事件死亡。
关键数值与推荐
- PD-L1 CPS≥1人群OS HR 0.62(95%CI 0.50-0.76),ITT人群OS HR 0.64(95%CI 0.53-0.78)。
- PD-L1 CPS≥1人群PFS HR 0.58(95%CI 0.48-0.71),ITT人群PFS HR 0.61(95%CI 0.51-0.74)。
临床怎么用
- 支持帕博利珠单抗联合铂类化疗(±贝伐珠单抗)作为持续性、复发性或转移性宫颈癌的一线标准治疗选项。
局限性
- 本分析为探索性分析,非预设主要分析。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the KEYNOTE-826 study, pembrolizumab (vs placebo) plus platinum-based chemotherapy (with or without bevacizumab) significantly improved progression-free survival and overall survival in participants with previously untreated persistent, recurrent, or metastatic cervical cancer at interim analysis 1 (median follow-up, 22.0 months), with continued benefit at final analysis (median follow-up, 39.1 months). Long-term follow-up is important to further inform the benefit-risk profile of anticancer treatments. OBJECTIVE: To investigate 5-year efficacy and safety results of pembrolizumab plus chemotherapy (with or without bevacizumab) in previously untreated persistent, recurrent, or metastatic cervical cancer. DESIGN, SETTING, AND PARTICIPANTS: This ad hoc exploratory analysis of the phase 3, double-blind KEYNOTE-826 randomized clinical trial was conducted in participants with previously untreated persistent, recurrent, or metastatic cervical cancer across 151 sites in 19 countries. Participants were randomly assigned to treatment between November 20, 2018, and January 31, 2020. The median follow-up for this analysis was 59.1 (range, 52.1-66.5) months (approximately 20 months after final analysis). Data were analyzed between November 20, 2018, and June 4, 2024. INTERVENTIONS: Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles vs placebo, each combined with platinum-based chemotherapy (with or without bevacizumab). MAIN OUTCOMES AND MEASURES: Progression-free survival and overall survival. RESULTS: A total of 617 female patients were randomized. At baseline, the median age of participants was 51.0 (range, 22-82) years, with 303 participants (49.1%) having stage I/II and 190 (30.8%) having IVB disease and 446 (72.3%) having squamous cell/squamous cell carcinoma. At 5 years, the overall survival benefit was sustained with pembrolizumab plus chemotherapy in the programmed cell death ligand 1 combined positive score of at least 1 (median [IQR], 28.6 [12.3 to not reached] vs 16.5 [9.0-40.5] months; hazard ratio [HR], 0.62 [95% CI, 0.50-0.76]) and intention-to-treat (median [IQR], 26.4 [12.0 to not reached] vs 16.8 [9.1-40.1] months; HR, 0.64 [95% CI, 0.53-0.78]) populations. The progression-free survival advantage was similarly maintained (median [IQR], 10.5 [6.2 to not reached] vs 8.2 [4.2-17.1] months; HR, 0.58 [95% CI, 0.48-0.71] and median [IQR], 10.4 [6.2 to not reached] vs 8.2 [4.3-15.5] months; HR, 0.61 [95% CI, 0.51-0.74], respectively). No new safety signals were observed. No additional deaths due to treatment-related adverse events had occurred since the final analysis. CONCLUSIONS AND RELEVANCE: In this exploratory analysis of the KEYNOTE-826 randomized clinical trial, the 5-year data confirm the durability of benefit and reinforce pembrolizumab plus chemotherapy (with or without bevacizumab) as a first-line standard-of-care option for recurrent and metastatic cervical cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03635567.
引用
- Hasegawa K, Colombo N, Tewari KS, et al. Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42720936. doi:10.1001/jamaoncol.2026.3547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。